FOXO1 repression contributes to block of plasma cell differentiation in classical Hodgkin lymphoma.

The survival of classical Hodgkin lymphoma (cHL) cells depends on activation of NF-κB, JAK/STAT, and IRF4. Whereas these factors typically induce the master regulator of plasma cell (PC) differentiation PRDM1/BLIMP-1, levels of PRDM1 remain low in cHL. FOXO1, playing a critical role in normal B-cell development, acts as a tumor suppressor in cHL, but has never been associated with induction of PC differentiation. Here we show that FOXO1 directly upregulates the full-length isoform PRDM1α in cHL cell lines. We also observed a positive correlation between FOXO1 and PRDM1 expression levels in primary Hodgkin-Reed-Sternberg cells. Further, we show that PRDM1α acts as a tumor suppressor in cHL at least partially by blocking MYC. Here we provide a link between FOXO1 repression and PRDM1α downregulation in cHL and identify PRDM1α as a tumor suppressor in cHL. The data support a potential role for FOXO transcription factors in normal PC differentiation.

[1]  R. Tooze.  A Replicative Self-Renewal Model for Long-Lived Plasma Cells: Questioning Irreversible Cell Cycle Exit , 2013, Front. Immunol..

[2]  E. Lam,et al.  FOXP1 acts through a negative feedback loop to suppress FOXO-induced apoptosis , 2013, Cell Death and Differentiation.

[3]  O. Elemento,et al.  Downregulation of FOXP1 is required during germinal center B-cell function. , 2013, Blood.

[4]  R. Küppers,et al.  Role of early B-cell factor 1 (EBF1) in Hodgkin lymphoma , 2013, Leukemia.

[5]  W. Klapper,et al.  Analyzing primary Hodgkin and Reed-Sternberg cells to capture the molecular and cellular pathogenesis of classical Hodgkin lymphoma. , 2012, Blood.

[6]  R. Gascoyne,et al.  Gene expression profiling of microdissected Hodgkin Reed-Sternberg cells correlates with treatment outcome in classical Hodgkin lymphoma. , 2012, Blood.

[7]  K. Wright,et al.  Hypomethylation and Over-Expression of the Beta Isoform of BLIMP1 is Induced by Epstein-Barr Virus Infection of B Cells; Potential Implications for the Pathogenesis of EBV-Associated Lymphomas , 2012, Pathogens.

[8]  T. Zhao,et al.  CD99 triggers upregulation of miR‐9‐modulated PRDM1/BLIMP1 in Hodgkin/Reed–Sternberg cells and induces redifferentiation , 2012, International journal of cancer.

[9]  Harald J. Maier,et al.  FOXO1 is a tumor suppressor in classical Hodgkin lymphoma. , 2012, Blood.

[10]  A. Schambach,et al.  A Differentiation Checkpoint Limits Hematopoietic Stem Cell Self-Renewal in Response to DNA Damage , 2012, Cell.

[11]  P. Murray,et al.  BLIMP1α, the master regulator of plasma cell differentiation is a tumor supressor gene in B cell lymphomas. , 2012, Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia.

[12]  Lixia Gan,et al.  FOXO1 increases CCL20 to promote NF-κB-dependent lymphocyte chemotaxis. , 2012, Molecular endocrinology.

[13]  P. Murray,et al.  BLIMP 1 α , THE MASTER REGULATOR OF PLASMA CELL DIFFERENTIATION IS A TUMOR SUPRESSOR GENE IN B CELL LYMPHOMAS , 2012 .

[14]  J. Paik,et al.  FoxO family members in cancer , 2011, Cancer biology & therapy.

[15]  K. Wright,et al.  Down-regulation of BLIMP1α by the EBV oncogene, LMP-1, disrupts the plasma cell differentiation program and prevents viral replication in B cells: implications for the pathogenesis of EBV-associated B-cell lymphomas. , 2011, Blood.

[16]  Ulf Leser,et al.  Classical Hodgkin’s lymphoma shows epigenetic features of abortive plasma cell differentiation , 2011, Haematologica.

[17]  A. Rosenwald,et al.  The MK5/PRAK kinase and Myc form a negative feedback loop that is disrupted during colorectal tumorigenesis. , 2011, Molecular cell.

[18]  Govind Bhagat,et al.  BLIMP1 is a tumor suppressor gene frequently disrupted in activated B cell-like diffuse large B cell lymphoma. , 2010, Cancer cell.

[19]  Christian Steidl,et al.  Cooperative epigenetic modulation by cancer amplicon genes. , 2010, Cancer cell.

[20]  J. Kutok,et al.  Constitutive canonical NF-κB activation cooperates with disruption of BLIMP1 in the pathogenesis of activated B cell-like diffuse large cell lymphoma. , 2010, Cancer cell.

[21]  Gerald C. Chu,et al.  FoxOs enforce a progression checkpoint to constrain mTORC1-activated renal tumorigenesis. , 2010, Cancer cell.

[22]  Zhi-xiang Shen,et al.  Loss of promoter methylation contributes to the expression of functionally impaired PRDM1β isoform in diffuse large B-cell lymphoma , 2010, International journal of hematology.

[23]  P. Möller,et al.  KLF4 is a tumor suppressor in B-cell non-Hodgkin lymphoma and in classic Hodgkin lymphoma. , 2010, Blood.

[24]  H. Allawi,et al.  Epigenetic down-regulation of the tumor suppressor gene PRDM1/Blimp-1 in diffuse large B cell lymphomas: a potential role of the microRNA let-7. , 2010, The American journal of pathology.

[25]  A. Carbone,et al.  The classical Hodgkin's lymphoma microenvironment and its role in promoting tumour growth and immune escape , 2010, The Journal of pathology.

[26]  L. Staudt.  Oncogenic activation of NF-kappaB. , 2010, Cold Spring Harbor perspectives in biology.

[27]  Trey Ideker,et al.  A global network of transcription factors, involving E2A, EBF1 and Foxo1, that orchestrates the B cell fate , 2010, Nature Immunology.

[28]  S. Crotty,et al.  Effectors and memories: Bcl-6 and Blimp-1 in T and B lymphocyte differentiation , 2010, Nature Immunology.

[29]  M. Kurokawa,et al.  Blimp-1 is a tumor suppressor gene in lymphoid malignancies , 2010, International journal of hematology.

[30]  B. Blom,et al.  New insights into the regulation of human B-cell differentiation. , 2009, Trends in immunology.

[31]  L. Staudt,et al.  IRF4: Immunity. Malignancy! Therapy? , 2009, Clinical Cancer Research.

[32]  R. Küppers,et al.  Pathogenesis of classical and lymphocyte-predominant Hodgkin lymphoma. , 2009, Annual review of pathology.

[33]  G. Radda,et al.  FoxO1 Inhibits Leptin Regulation of Pro-opiomelanocortin Promoter Activity by Blocking STAT3 Interaction with Specificity Protein 1* , 2009, Journal of Biological Chemistry.

[34]  R. deLeeuw,et al.  Genomic analyses reveal global functional alterations that promote tumor growth and novel tumor suppressor genes in natural killer-cell malignancies , 2009, Leukemia.

[35]  Ralf Küppers,et al.  The biology of Hodgkin's lymphoma , 2009, Nature Reviews Cancer.

[36]  T. Tuschl,et al.  Tumorigenesis and Neoplastic Progression MicroRNA-Mediated Down-Regulation of PRDM 1 / Blimp-1 in Hodgkin / Reed-Sternberg Cells : A Potential Pathogenetic Lesion in Hodgkin Lymphomas , 2010 .

[37]  M. Schlissel,et al.  Foxo1 directly regulates the transcription of recombination-activating genes during B cell development , 2008, Nature Immunology.

[38]  L. Staudt,et al.  Cooperative signaling through the signal transducer and activator of transcription 3 and nuclear factor-{kappa}B pathways in subtypes of diffuse large B-cell lymphoma. , 2008, Blood.

[39]  Hergen Spits,et al.  STAT3-Mediated Up-Regulation of BLIMP1 Is Coordinated with BCL6 Down-Regulation to Control Human Plasma Cell Differentiation1 , 2008, The Journal of Immunology.

[40]  R. DePinho,et al.  Distinct functions for the transcription factor Foxo1 at various stages of B cell differentiation , 2008, Nature Immunology.

[41]  K. Basso,et al.  A signaling pathway mediating downregulation of BCL6 in germinal center B cells is blocked by BCL6 gene alterations in B cell lymphoma. , 2007, Cancer cell.

[42]  Zhi-xiang Shen,et al.  Rituximab plus CHOP (R-CHOP) overcomes PRDM1-associated resistance to chemotherapy in patients with diffuse large B-cell lymphoma. , 2007, Blood.

[43]  K. Calame,et al.  Regulation of class-switch recombination and plasma cell differentiation by phosphatidylinositol 3-kinase signaling. , 2006, Immunity.

[44]  W. Chan,et al.  Mutational analysis of PRDM1 indicates a tumor-suppressor role in diffuse large B-cell lymphomas. , 2006, Blood.

[45]  Sergey W. Popov,et al.  Epigenetic processes play a major role in B-cell-specific gene silencing in classical Hodgkin lymphoma. , 2006, Blood.

[46]  H. Stein,et al.  Intrinsic inhibition of transcription factor E2A by HLH proteins ABF-1 and Id2 mediates reprogramming of neoplastic B cells in Hodgkin lymphoma , 2006, Nature Immunology.

[47]  F. Mora-López,et al.  The expression of PRDI-BF1 beta isoform in multiple myeloma plasma cells. , 2006, Haematologica.

[48]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[49]  H. Jäck,et al.  Evidence of abortive plasma cell differentiation in Hodgkin and Reed‐Sternberg cells of classical Hodgkin lymphoma , 2005, Hematological oncology.

[50]  N. Schoof,et al.  STAT3 is essential for Hodgkin lymphoma cell proliferation and is a target of tyrphostin AG17 which confers sensitization for apoptosis , 2005, Leukemia.

[51]  V. Ogryzko,et al.  Codon optimization of the BirA enzyme gene leads to higher expression and an improved efficiency of biotinylation of target proteins in mammalian cells. , 2005, Journal of biotechnology.

[52]  A. Banham,et al.  The FOXP1 Transcription Factor is Expressed in the Majority of Follicular Lymphomas but is Rarely Expressed in Classical and Lymphocyte Predominant Hodgkin’s Lymphoma , 2005, Journal of Molecular Histology.

[53]  P. Lipsky,et al.  Regulation of B Cell Differentiation and Plasma Cell Generation by IL-21, a Novel Inducer of Blimp-1 and Bcl-61 , 2004, The Journal of Immunology.

[54]  Jonathan D. Hron,et al.  Regulation of NF-kappaB, Th activation, and autoinflammation by the forkhead transcription factor Foxo3a. , 2004, Immunity.

[55]  C. Hughes,et al.  Of Mice and Not Men: Differences between Mouse and Human Immunology , 2004, The Journal of Immunology.

[56]  K. Wright,et al.  Identification of a Functionally Impaired Positive Regulatory Domain I Binding Factor 1 Transcription Repressor in Myeloma Cell Lines1 , 2003, The Journal of Immunology.

[57]  P. Heinrich,et al.  Akt Modulates STAT3-mediated Gene Expression through a FKHR (FOXO1a)-dependent Mechanism* , 2003, The Journal of Biological Chemistry.

[58]  Liming Yang,et al.  Blimp-1 orchestrates plasma cell differentiation by extinguishing the mature B cell gene expression program. , 2002, Immunity.

[59]  G. Gaidano,et al.  Expression pattern of MUM1/IRF4 in the spectrum of pathology of Hodgkin's disease , 2002, British journal of haematology.

[60]  D. Dowbenko,et al.  The Forkhead Transcription Factor AFX Activates Apoptosis by Induction of the BCL-6 Transcriptional Repressor* , 2002, The Journal of Biological Chemistry.

[61]  K. Calame,et al.  Transcriptional Repression by Blimp-1 (PRDI-BF1) Involves Recruitment of Histone Deacetylase , 2000, Molecular and Cellular Biology.

[62]  B. Dörken,et al.  Constitutive nuclear factor-kappaB-RelA activation is required for proliferation and survival of Hodgkin's disease tumor cells. , 1997, The Journal of clinical investigation.

[63]  K. Calame,et al.  Repression of c-myc transcription by Blimp-1, an inducer of terminal B cell differentiation. , 1997, Science.

[64]  R. Warnke,et al.  SUP-HD1: a new Hodgkin's disease-derived cell line with lymphoid features produces interferon-gamma. , 1989, Blood.

[65]  R. Roeder,et al.  Eukaryotic gene transcription with purified components. , 1983, Methods in enzymology.